However, since 60% of SMA patients usually carry only two SMN2 copies and develop the severe form of SMA, augmenting the SMN level solely via splice correction molecules seems to be insufficient to cure SMA (Finkel et al., 2017; Mercuri et al., 2018a). Here, SMN1 is linked to proximal spinal muscular atrophy.